Tag: KaloBios

Posted on

KaloBios to Stop KB003 Development for Asthma – Analyst Blog – NASDAQ

KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ
KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant …
KaloBios shares tank on failed asthma drug trialSan Francisco Business Times (blog)
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
MarketWatch
all 32 news articles »

View full post on asthma – Google News

Posted on

KaloBios shares tank on failed asthma drug trial – San Francisco Business Times (blog)

KaloBios shares tank on failed asthma drug trial
San Francisco Business Times (blog)
KaloBios (NASDAQ: KBIO), which has seen its stock price tumble since it raised $70 million in an initial public offering a year ago, will discontinue clinical development of the drug, called KB-003, in severe asthma. The monoclonal antibody was safe …
KaloBios to Stop KB003 Development for AsthmaZacks.com
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
Wall Street Journal
all 31 news articles »

View full post on asthma – Google News

Posted on

KaloBios to Stop KB003 Development for Asthma – Zacks.com

KaloBios to Stop KB003 Development for Asthma
Zacks.com
KaloBios Pharmaceuticals, Inc. (KBIO – Snapshot Report) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a …
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios Shares Slide on Move to Stop Asthma Treatment StudyWall Street Journal
RTT News –San Francisco Business Times (blog)
all 30 news articles »

View full post on asthma – Google News

Posted on

KaloBios calls it quits on its asthma drug after a Phase II flop – FierceBiotech

KaloBios calls it quits on its asthma drug after a Phase II flop
FierceBiotech
San Francisco's KaloBios ($KBIO) is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin. The drug, KB003, failed to significantly …
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios stock slides; to stop asthma studyMarketWatch
KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma StudyRTT News
San Francisco Business Times (blog)
all 29 news articles »

View full post on asthma – Google News

Posted on

KaloBios Pharma pulls plug on asthma drug, shares plunge – Reuters

KaloBios Pharma pulls plug on asthma drug, shares plunge
Reuters
(Reuters) – Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study. The drug, KB003, failed to bring about a clinically meaningful …
KaloBios stock slides; to stop asthma studyMarketWatch
KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma StudyRTT News

all 19 news articles »

View full post on asthma – Google News

Posted on

KaloBios stock slides; to stop asthma study – MarketWatch

KaloBios stock slides; to stop asthma study
MarketWatch
KaloBios Pharmaceuticals Inc.'s (NASDAQ:KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said …
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma …Benzinga

all 2 news articles »

View full post on asthma – Google News

Posted on

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal … – The Herald | HeraldOnline.com

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal …
The Herald | HeraldOnline.com
KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma …

and more »

View full post on asthma – Google News